白细胞介素-2

白细胞介素-2
已知的结构
PDB	直系同源搜索: PDBe RCSB
PDBID列表
	1IRL、1M47、1M48、1M49、1M4A、1M4B、1M4C、1NBP、1PW6、1PY2、1QVN、1Z92、2B5I、2ERJ、3QAZ、3QB1、3INK、4NEJ、4NEM
识别号
别名	IL2；, IL-2, TCGF, lymphokine, interleukin 2
外部ID	OMIM：147680 MGI：96548 HomoloGene：488 GeneCards：IL2
相关疾病
	过敏、1型糖尿病
基因位置（人类）
染色体	4号染色体
终止	122,456,725 bp
基因位置（小鼠）
染色体	小鼠3号染色体
终止	37,180,108 bp
RNA表达模式
	查阅更多表达数据
基因本体
分子功能	• 细胞因子活性; • interleukin-2 receptor binding; • glycosphingolipid binding; • kinase activator activity; • 生长因子活性; • kappa-type opioid receptor binding; • carbohydrate binding; • 血浆蛋白结合;
细胞组分	• 细胞外区域; • 胞内; • 细胞外空间;
生物学过程	• positive regulation of T cell differentiation; • negative regulation of protein phosphorylation; • G protein-coupled receptor signaling pathway; • positive regulation of protein phosphorylation; • positive regulation of inflammatory response; • adaptive immune response; • negative regulation of heart contraction; • immune system process; • positive regulation of cytosolic calcium ion concentration; • positive regulation of regulatory T cell differentiation; • cell-cell signaling; • positive regulation of interferon-gamma production; • natural killer cell activation; • negative regulation of apoptotic process; • positive regulation of dendritic spine development; • negative regulation of lymphocyte proliferation; • MAPK cascade; • regulation of T cell homeostatic proliferation; • T cell differentiation; • positive regulation of cell growth; • protein kinase C-activating G protein-coupled receptor signaling pathway; • 细胞粘附; • positive regulation of B cell proliferation; • positive regulation of tissue remodeling; • positive regulation of T cell proliferation; • 免疫反应; • positive regulation of cell population proliferation; • extrinsic apoptotic signaling pathway in absence of ligand; • negative regulation of B cell apoptotic process; • positive regulation of isotype switching to IgG isotypes; • positive regulation of interleukin-17 production; • response to ethanol; • negative regulation of inflammatory response; • positive regulation of transcription by RNA polymerase II; • positive regulation of activated T cell proliferation; • negative regulation of T-helper 17 cell differentiation; • leukocyte activation involved in immune response; • positive regulation of tyrosine phosphorylation of STAT protein; • regulation of regulatory T cell differentiation; • regulation of signaling receptor activity; • cytokine-mediated signaling pathway; • interleukin-2-mediated signaling pathway; • positive regulation of kinase activity;
	Sources:Amigo / QuickGO
直系同源
	3558
	16183
	ENSG00000109471
	ENSMUSG00000027720
	P60568
	P04351
	NM_000586
	NM_008366
	NP_000577
	NP_032392
	维基数据
查看/编辑人类	查看/编辑小鼠

白细胞介素2 (英语：Interleukin 2，IL-2)是细胞因子中白细胞介素的一种，在免疫系统中起重要作用。它是一种蛋白质，负责调节白细胞（白细胞，通常是淋巴细胞）的免疫活性。 IL-2的生成是机体受微生物感染时免疫应答的一部分，以区别“自己”与“非己”。IL-2通过与淋巴细胞表面的IL-2 受体结合来发挥作用。

信号通路

IL-2是拥有四个α螺旋束的细胞因子家族的一员，这一家族包括IL-4、IL-7、IL-9、IL-15和IL-21。IL-2的信号通过与之结合的IL-2受体传导到胞内，IL-2受体是由α、β、γ三条链组成的异聚体，其中γ链为本家族所有IL的受体共有^[6]。

当IL-2受体α亚基（IL-2RA）单独存在时，其与配体的亲和力只有完整的IL-2受体（包含了β、γ亚基）的百分之一，β和γ亚基的参与对IL-2R参与T细胞的信号转导是必要的^[7]。

历史

发现

作为免疫系统的一种水溶性分子，白细胞介素2是第一种被发现并被克隆的白细胞介素，其对应受体也是第一个被克隆并被解析结构的I型细胞因子受体。^[8]^:712

在1960年代中期，有研究报道了白细胞条件培养基中有促进淋巴细胞增殖的“活性因子”^[9]^:16。在1970年代中期，又发现了正常的人骨髓细胞可在某种条件性培养基中选择性的使T细胞扩增，此条件性培养基用由植物血凝素刺激人正常淋巴细胞而来^[8]^:712。这其中的关键因子被称为白细胞介素2，源自鼠细胞的白细胞介素2于1979年分离纯化，人细胞源的分离纯化于1980年^[10]。在多个实验室的激烈竞争中，人IL-2基因最终在1982年被克隆^[11]^:76。

应用

IL-2的促免疫活性使得其在20世纪八九十年代成为一种有希望进入医药市场的免疫增强药物。在1983年，Cetus公司制得了修饰重组的人IL-2蛋白（去掉了氨基端的丙氨酸，125号位的丝氨酸换为半胱氨酸）并冠以商品名Aldesleukin（后期改为Proleukin）^[11]^:76–77^[12]^:201^[13]。此后，安进公司也进入了这一领域，制得了自己的重组/突变蛋白，很快两家公司就对簿公堂，Cetus最终赢得了专利诉讼将安进逐出了此领域^[11]^:151。在1990年，Cetus的aldesleukin获得了九个欧洲国家的批准，但是在同年，美国食品药品监督管理局（FDA）拒绝了Cetus的aldesleukin上市申请^[14]。这一失利导致了Cetus公司的破产，并于1991年被Chiron公司收购^[15]^[16]。此后，Chiron公司继续开发IL-2，并在1992年以Proleukin为商品名获得了FDA的批准，用以治疗转移性的肾细胞癌^[17]。

截止1993年，Proleukin仍是唯一获得批准的IL-2药物，但此时罗氏公司也开发了自己的修饰的IL-2（在氨基端增加了甲硫氨酸）商品名为teceleukin，Glaxo公司也发展的新药bioleukin，在氨基端增加了甲硫氨酸，125号残基替换为丙氨酸。此后，又有数十种基于IL-2及联合其它免疫因子的病人血细胞刺激回输方法被开发出来^[13]^[18]。

参考文献

^ 與白细胞介素-2相關的疾病；在維基數據上查看/編輯參考.
^ ^2.0 ^2.1 ^2.2 GRCh38: Ensembl release 89: ENSG00000109471 - Ensembl, May 2017
^ ^3.0 ^3.1 ^3.2 GRCm38: Ensembl release 89: ENSMUSG00000027720 - Ensembl, May 2017
^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology. October 2011, 23 (5): 598–604. PMC 3405730 . PMID 21889323. doi:10.1016/j.coi.2011.08.003.
^ Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. November 2004, 28 (3): 109–23. PMID 15473953. doi:10.1016/j.cyto.2004.06.010.
^ ^8.0 ^8.1 Paul WE. Fundamental immunology 6th. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2008. ISBN 978-0-7817-6519-0.
^ Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT. Pharmacologic administration of interleukin-2. Annals of the New York Academy of Sciences. December 2009, 1182: 14–27. PMID 20074271. doi:10.1111/j.1749-6632.2009.05160.x.
^ Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA. Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. The Journal of Experimental Medicine. August 1982, 156 (2): 454–64. PMC 2186775 . PMID 6980256. doi:10.1084/jem.156.2.454.
^ ^11.0 ^11.1 ^11.2 Rabinow P. Making PCR: A story of biotechnology Paperback. Chicago, IL, USA: University of Chicago Press. 1997. ISBN 978-0226701479.
^ Hugo Almeida. Drugs obtained by biotechnology processing （页面存档备份，存于互联网档案馆） Brazilian Journal of Pharmaceutical Sciences apr/jun 2011 47(2):199-207
^ ^13.0 ^13.1 Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. September 1993, 46 (3): 446–514. PMID 7693434. doi:10.2165/00003495-199346030-00009.
^ Pollack A. Cetus Drug Is Blocked By F.D.A.. New York Times. July 31, 1990 [2017-06-25]. （原始内容存档于2020-09-28）. This source mentions approval in 9 European countries.
^ 2 Biotech Pioneers To Merge. New York Times. July 23, 1991 [2017-06-25]. （原始内容存档于2021-12-02）.
^ Lehrman S. Cetus: A Collision Course With Failure. The Scientist Magazine. January 20, 1992 [2022-01-18]. （原始内容存档于2016-08-05）.
^ Dutcher JP. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology. November 2002, 16 (11 Suppl 13): 4–10. PMID 12469934.
^ D02749 (Teceleukin). KEGG drug. （原始内容存档于2021-11-01）.

外部链接

Proleukin website （页面存档备份，存于互联网档案馆）
IL2 Resource Site
IL-2 Signaling Pathway （页面存档备份，存于互联网档案馆）

分类

[1] 與白细胞介素-2相關的疾病；在維基數據上查看/編輯參考.

[refGRCh38Ensembl-2] 2.0 ^2.1 ^2.2 GRCh38: Ensembl release 89: ENSG00000109471 - Ensembl, May 2017

[refGRCm38Ensembl-3] 3.0 ^3.1 ^3.2 GRCm38: Ensembl release 89: ENSMUSG00000027720 - Ensembl, May 2017

[4] Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.

[5] Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.

[Liao_2011-6] Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology. October 2011, 23 (5): 598–604. PMC 3405730 . PMID 21889323. doi:10.1016/j.coi.2011.08.003.

[Gaffen_2004-7] Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. November 2004, 28 (3): 109–23. PMID 15473953. doi:10.1016/j.cyto.2004.06.010.

[Leonard-8] 8.0 ^8.1 Paul WE. Fundamental immunology 6th. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2008. ISBN 978-0-7817-6519-0.

[pmid20074271-9] Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT. Pharmacologic administration of interleukin-2. Annals of the New York Academy of Sciences. December 2009, 1182: 14–27. PMID 20074271. doi:10.1111/j.1749-6632.2009.05160.x.

[pmid6980256-10] Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA. Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. The Journal of Experimental Medicine. August 1982, 156 (2): 454–64. PMC 2186775 . PMID 6980256. doi:10.1084/jem.156.2.454.

[CetusHist-11] 11.0 ^11.1 ^11.2 Rabinow P. Making PCR: A story of biotechnology Paperback. Chicago, IL, USA: University of Chicago Press. 1997. ISBN 978-0226701479.

[12] Hugo Almeida. Drugs obtained by biotechnology processing （页面存档备份，存于互联网档案馆） Brazilian Journal of Pharmaceutical Sciences apr/jun 2011 47(2):199-207

[Whittington_1993-13] 13.0 ^13.1 Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. September 1993, 46 (3): 446–514. PMID 7693434. doi:10.2165/00003495-199346030-00009.

[Pollack_1990-14] Pollack A. Cetus Drug Is Blocked By F.D.A.. New York Times. July 31, 1990 [2017-06-25]. （原始内容存档于2020-09-28）. This source mentions approval in 9 European countries.

[Pollack_1991-15] 2 Biotech Pioneers To Merge. New York Times. July 23, 1991 [2017-06-25]. （原始内容存档于2021-12-02）.

[Lehrman_1992-16] Lehrman S. Cetus: A Collision Course With Failure. The Scientist Magazine. January 20, 1992 [2022-01-18]. （原始内容存档于2016-08-05）.

[pmid12469934-17] Dutcher JP. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology. November 2002, 16 (11 Suppl 13): 4–10. PMID 12469934.

[urlKEGG_DRUG:_D02749-18] D02749 (Teceleukin). KEGG drug. （原始内容存档于2021-11-01）.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

白细胞介素-2

信号通路

历史

发现

应用

参考文献

外部链接

Suggest as cover photo

Thank you for helping!

Install Wikiwand

Don't forget to rate us

Tell your friends about Wikiwand!

Enjoying Wikiwand?

Tell your friends and spread the love:

Your preferred languages

All languages

Follow Us

Don't forget to rate us

Our magic isn't perfect

Thank you for helping!

Oh no, there's been an error